China' SFDA clears China Pharma's granisetron
China Pharma Holdings say it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market its granisetron HCl injection. This is a generic version of GlaxoSmithKline's Kytril.
The product is indicated for the prevention of nausea and vomiting associated with radiation treatment and chemotherapy in cancer patients. It is a highly-selective receptor antagonist against 5-hydroxytryptamine 3(5-HT3), which is produced during chemotherapy and radiation treatment that triggers emetic reactions in these patients. Granisetron is a prescription drug and is administered within 30 minutes before initiation of chemotherapy treatment.
China Pharma intends to market this product exclusively within the greater China area. Currently, sales statistics for granisetron products in China are not available, however, the market for injectable granisetron is valued over $1.0 billion in the USA and Canada.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze